Clinical Trial

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2025 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is to evaluate the efficacy and safety of chemotherapy combined with or without immunotherapy as postoperative adjuvant regimens in patients with resectable gastric cancer/adenocarcinoma of the esophagogastric junction after radical surgery
Trial Details
NCT Number NCT07149181
Lead Sponsor Liaoning Cancer Hospital & Institute
Conditions Gastric / Gastroesophageal Junction Adenocarcinoma
Enrollment 1,000 participants
Start Date 2025-08-31
Primary Completion 2025-08-31 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-29